You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 18, 2024

PROPRANOLOL HYDROCHLORIDE - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for propranolol hydrochloride and what is the scope of patent protection?

Propranolol hydrochloride is the generic ingredient in six branded drugs marketed by Ani Pharms, Actavis Elizabeth, Adare Pharms Inc, Amta, Inwood Labs, Lupin Ltd, Nortec Dev Assoc, Rising, Upsher Smith Labs, Zydus Pharms Usa Inc, Roxane, Baxter Hlthcare Corp, Chartwell Injectable, Fosun Pharma, Fresenius Kabi Usa, Hikma Farmaceutica, Smith And Nephew, Solopak, Pierre Fabre, Hikma, Pai Holdings Pharm, Wyeth Ayerst, Wyeth Pharms, Aiping Pharm Inc, Chartwell Rx, Dava Pharms Inc, Duramed Pharms Barr, Endo Operations, Impax Labs Inc, Innogenix, Interpharm, Ipca Labs Ltd, Ivax Sub Teva Pharms, Lederle, Mylan, Northstar Hlthcare, Purepac Pharm, Sandoz, Schering, Superpharm, Teva, Warner Chilcott, Watson Labs, and Watson Labs Teva, and is included in one hundred and twenty-six NDAs. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Propranolol hydrochloride has forty-seven patent family members in thirty-one countries.

There are ten drug master file entries for propranolol hydrochloride. Forty-one suppliers are listed for this compound.

Summary for PROPRANOLOL HYDROCHLORIDE
Recent Clinical Trials for PROPRANOLOL HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
AIDS Malignancy ConsortiumPhase 2
Rigshospitalet, DenmarkPhase 2
Zealand University HospitalPhase 2

See all PROPRANOLOL HYDROCHLORIDE clinical trials

Pharmacology for PROPRANOLOL HYDROCHLORIDE
Medical Subject Heading (MeSH) Categories for PROPRANOLOL HYDROCHLORIDE
Anatomical Therapeutic Chemical (ATC) Classes for PROPRANOLOL HYDROCHLORIDE
Paragraph IV (Patent) Challenges for PROPRANOLOL HYDROCHLORIDE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
HEMANGEOL Oral Solution propranolol hydrochloride 4.28 mg/mL 205410 1 2022-07-21

US Patents and Regulatory Information for PROPRANOLOL HYDROCHLORIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Solopak PROPRANOLOL HYDROCHLORIDE propranolol hydrochloride INJECTABLE;INJECTION 070136-001 Apr 15, 1986 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Innogenix PROPRANOLOL HYDROCHLORIDE propranolol hydrochloride TABLET;ORAL 070322-001 Aug 4, 1986 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Impax Labs Inc PROPRANOLOL HYDROCHLORIDE propranolol hydrochloride TABLET;ORAL 071972-002 Apr 6, 1988 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Inwood Labs PROPRANOLOL HYDROCHLORIDE propranolol hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 072501-001 Apr 11, 1989 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Ipca Labs Ltd PROPRANOLOL HYDROCHLORIDE propranolol hydrochloride TABLET;ORAL 078955-004 Jun 2, 2008 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Northstar Hlthcare PROPRANOLOL HYDROCHLORIDE propranolol hydrochloride TABLET;ORAL 078213-005 Jan 10, 2008 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Interpharm PROPRANOLOL HYDROCHLORIDE propranolol hydrochloride TABLET;ORAL 071371-001 May 5, 1987 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for PROPRANOLOL HYDROCHLORIDE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ani Pharms INDERAL LA propranolol hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 018553-004 Mar 18, 1987 ⤷  Sign Up ⤷  Sign Up
Ani Pharms INDERAL LA propranolol hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 018553-001 Apr 19, 1983 ⤷  Sign Up ⤷  Sign Up
Ani Pharms INNOPRAN XL propranolol hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021438-001 Mar 12, 2003 ⤷  Sign Up ⤷  Sign Up
Wyeth Ayerst INDERAL propranolol hydrochloride SUSPENSION;ORAL 019536-001 Dec 12, 1986 ⤷  Sign Up ⤷  Sign Up
Ani Pharms INNOPRAN XL propranolol hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021438-002 Mar 12, 2003 ⤷  Sign Up ⤷  Sign Up
Ani Pharms INDERAL LA propranolol hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 018553-003 Apr 19, 1983 ⤷  Sign Up ⤷  Sign Up
Ani Pharms INDERAL LA propranolol hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 018553-002 Apr 19, 1983 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for PROPRANOLOL HYDROCHLORIDE

Country Patent Number Title Estimated Expiration
Taiwan 200932207 Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas ⤷  Sign Up
European Patent Office 2233135 Utilisation de bêtabloquants pour la fabrication d'un médicament pour le traitement d'hémangiomes (Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas) ⤷  Sign Up
Taiwan I531365 ⤷  Sign Up
Colombia 6270209 UN BETA BLOQUEANTE PARA EL TRATAMIENTO DE LOS HEMANGIOMAS ⤷  Sign Up
Poland 2233135 ⤷  Sign Up
Portugal 2187878 ⤷  Sign Up
Poland 2187878 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.